Application Note: Highly selective bioanalytical quantitation method for analysis of R and S amlodipine enantiomers in human plasma using LC-MS/MS
Amlodipine is an angioselective calcium channel blocker used to treat high blood pressure, chest pain and other conditions caused by coronary artery disease.
Racemic mixture of amlodipine is used for therapeutic purposes. S amlodipine is the pharmacologically active enantiomer of amlodipine. The use of racemic mixture of amlodipine showed adverse effects like peripheral edema, headache, dizziness, flushing and abdominal pain. Studies have reported these adverse effects are rarely associated with S Amlodipine. R and S enantiomers of amlodipine exhibit different pharmacokinetics and pharmacodynamics. Here we present a Selective LC-MS/MS method, developed to monitor concentrations of R and S enantiomers of amlodipine in human plasma to evaluate the pharmaceutical equivalence for both racemic and S amlodipine formulations of amlodipine.
The rest of this content is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- bi-monthly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Related content from this organisation
- Application Note: Highly selective bioanalytical quantitation method for analysis of R and S amlodipine enantiomers in human plasma using LC-MS/MS
- Application Note: Simultaneous quantitation/profiling of cell culture medium components using LC-MS/MS
- Application Note: Quantitation of intact therapeutic protein in plasma matrix by LC/MS
- Overcoming unusual challenges in the characterisation of a monoclonal antibodies by LC-MS from early to late stage of development
- SCIEX announces latest innovations for improving healthcare and well-being at ASMS